Rechallenge with temozolomide in recurrent glioma

P. Gaviani, A. Silvani, E. Lamperti, A. Botturi, L. Fariselli, G. Simonetti, D. Ferrari, A. Salmaggi

Research output: Contribution to journalArticle

Abstract

Despite a confirmed survival benefit associated with adjuvant radio- and chemotherapy, the majority of patients with malignant glioma relapse after initial therapy. Recurrent malignant glioma treatment has not been standardised and usually the response rate to standard chemotherapy protocols for recurrent malignant glioma is less than 30%. The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment. The most widely studied regimens in this setting include (1) 21 of 28-day schedule at a dose of 75-100 mg/m2/day; (2) 7 of 14-day schedule at a dose of 150 mg/m2/day, also referred to as the ''one week on/one week off'' schedule; (3) Continuous daily schedule at a dose of 50 mg/m2/day. An alternative dosing schedule of TMZ may be a reasonable option in patients having high-grade gliomas with recurrence after standard therapy.

Original languageEnglish
Pages (from-to)1-3
Number of pages3
JournalNeurological Sciences
DOIs
Publication statusAccepted/In press - 2011

Fingerprint

temozolomide
Glioma
Appointments and Schedules
Methyltransferases
Therapeutics
Recurrence
Adjuvant Radiotherapy
Alkylating Agents
Adjuvant Chemotherapy

Keywords

  • Dose-dense
  • Recurrent glioma
  • Salvage chemotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology
  • Dermatology

Cite this

Rechallenge with temozolomide in recurrent glioma. / Gaviani, P.; Silvani, A.; Lamperti, E.; Botturi, A.; Fariselli, L.; Simonetti, G.; Ferrari, D.; Salmaggi, A.

In: Neurological Sciences, 2011, p. 1-3.

Research output: Contribution to journalArticle

@article{b6310caf56a44acebb102f367e431c4d,
title = "Rechallenge with temozolomide in recurrent glioma",
abstract = "Despite a confirmed survival benefit associated with adjuvant radio- and chemotherapy, the majority of patients with malignant glioma relapse after initial therapy. Recurrent malignant glioma treatment has not been standardised and usually the response rate to standard chemotherapy protocols for recurrent malignant glioma is less than 30{\%}. The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment. The most widely studied regimens in this setting include (1) 21 of 28-day schedule at a dose of 75-100 mg/m2/day; (2) 7 of 14-day schedule at a dose of 150 mg/m2/day, also referred to as the ''one week on/one week off'' schedule; (3) Continuous daily schedule at a dose of 50 mg/m2/day. An alternative dosing schedule of TMZ may be a reasonable option in patients having high-grade gliomas with recurrence after standard therapy.",
keywords = "Dose-dense, Recurrent glioma, Salvage chemotherapy, Temozolomide",
author = "P. Gaviani and A. Silvani and E. Lamperti and A. Botturi and L. Fariselli and G. Simonetti and D. Ferrari and A. Salmaggi",
year = "2011",
doi = "10.1007/s10072-011-0798-7",
language = "English",
pages = "1--3",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",

}

TY - JOUR

T1 - Rechallenge with temozolomide in recurrent glioma

AU - Gaviani, P.

AU - Silvani, A.

AU - Lamperti, E.

AU - Botturi, A.

AU - Fariselli, L.

AU - Simonetti, G.

AU - Ferrari, D.

AU - Salmaggi, A.

PY - 2011

Y1 - 2011

N2 - Despite a confirmed survival benefit associated with adjuvant radio- and chemotherapy, the majority of patients with malignant glioma relapse after initial therapy. Recurrent malignant glioma treatment has not been standardised and usually the response rate to standard chemotherapy protocols for recurrent malignant glioma is less than 30%. The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment. The most widely studied regimens in this setting include (1) 21 of 28-day schedule at a dose of 75-100 mg/m2/day; (2) 7 of 14-day schedule at a dose of 150 mg/m2/day, also referred to as the ''one week on/one week off'' schedule; (3) Continuous daily schedule at a dose of 50 mg/m2/day. An alternative dosing schedule of TMZ may be a reasonable option in patients having high-grade gliomas with recurrence after standard therapy.

AB - Despite a confirmed survival benefit associated with adjuvant radio- and chemotherapy, the majority of patients with malignant glioma relapse after initial therapy. Recurrent malignant glioma treatment has not been standardised and usually the response rate to standard chemotherapy protocols for recurrent malignant glioma is less than 30%. The growing body of evidence demonstrating the clinical importance of O6-methylguanine methyltransferase (MGMT) has generated a considerable interest in the exploration of strategies to overcome MGMT-mediated resistance to alkylating agents; for example protracted administration of Temozolomide (TMZ) may result in more extensive and sustained depletion of MGMT; for this reason a variety of dosing schedules that increase the duration of exposure and the cumulative dose of TMZ are being investigated for the treatment of patient with recurrent malignant glioma after standard treatment. The most widely studied regimens in this setting include (1) 21 of 28-day schedule at a dose of 75-100 mg/m2/day; (2) 7 of 14-day schedule at a dose of 150 mg/m2/day, also referred to as the ''one week on/one week off'' schedule; (3) Continuous daily schedule at a dose of 50 mg/m2/day. An alternative dosing schedule of TMZ may be a reasonable option in patients having high-grade gliomas with recurrence after standard therapy.

KW - Dose-dense

KW - Recurrent glioma

KW - Salvage chemotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=80053471318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053471318&partnerID=8YFLogxK

U2 - 10.1007/s10072-011-0798-7

DO - 10.1007/s10072-011-0798-7

M3 - Article

SP - 1

EP - 3

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

ER -